Sepsis, systemic inflammatory response, and multiple organ dysfunction: The mystery continues

American Surgeon

Volumn 78, Issue 1, 2012, Pages 1-8

  Fry, Donald E ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BRADYKININ ANTAGONIST; CORTICOSTEROID; DROTRECOGIN; ENDOTOXIN ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; STEROID; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

BACTEREMIA; BLEEDING DISORDER; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOTOXEMIA; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; NOTE; PHAGOCYTOSIS; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC THERAPY; VASODILATATION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE ORGAN FAILURE; PROTEIN C INHIBITOR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857090358     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (69)

1. Goris RJ, Beokhorst PA, Nuytinck KS. Multiple organ failure: generalized autodestructive inflammation. Arch Surg 1985; 120:1109-15. (Pubitemid 16229682)
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
3. Klune JR, Tsung A. Molecular biology of liver ischemia/reperfusion injury: established mechanisms and recent advancements. Surg Clin North Am 2010;90:665-77.
4. Fry DE. Sepsis syndrome. Am Surg 2000;66:126-32. (Pubitemid 30106294)
5. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004;79:103-8. (Pubitemid 38281807)
6. Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest 2008;118:3006-9.
7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5. (Pubitemid 46028489)
8. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86. (Pubitemid 41598688)
9. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009;22: 240-73.
10. Kawai T, Akira S. The roles of TLRs, RLRs, and NLRs in pathogen recognition. Int Immunol 2009;21:317-37.
11. Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88.
12. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
13. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-21. (Pubitemid 43209108)
14. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg 1973;178:117-22.
15. Eiseman B, Beart R, Norton L. Multiple organ failure. Surg Gynecol Obstet 1977;144:323-6. (Pubitemid 8198652)
16. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr. Multiple system organ failure: the role of uncontrolled infection. Arch Surg 1980;115:136-40. (Pubitemid 10162823)
17. Lillehei RC, Longerbeam JK, Bloch JH, Manax WG. The nature of irreversible shock: experimental and clinical observations. Ann Surg 1964;160:682-708.
18. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984;311:1137-43. (Pubitemid 14012580)
19. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8. (Pubitemid 17138189)
20. Hinshaw L, Peduzzi P, Young E, et al. The Veterans administration systemic sepsis cooperative study group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65. (Pubitemid 17138190)
21. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:653-8.
22. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
23. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisones on mortality in patients with septic shock. JAMA 2002;288:862-71.
24. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009;15: 308-18.
25. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75.
26. Dunn DL, Ferguson RM. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 1982;92:212-9. (Pubitemid 13091504)
27. Dunn DL. Antibody immunotherapy of gram-negative bacterial sepsis. Pharmacotherapy 1987;7:S31-5. (Pubitemid 17117106)
28. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30. (Pubitemid 12001356)
29. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med 1991;324:429-36.
30. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Intern Med 1994;121:1-5.
31. Schirmer WJ, Schirmer JM, Fry DE. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 1989;124:445-8. (Pubitemid 19106434)
32. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985;229:869-71. (Pubitemid 16246587)
33. Tracey KJ, Fong Y, Hesse DG, et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662-4. (Pubitemid 18005583)
34. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
35. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 1996;24:733-42.
36. Cohen J, Carlet J. INTERSEPT: an international, multi-center, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431-40. (Pubitemid 26313741)
37. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929-33. (Pubitemid 28138465)
38. Loetscher H, Gentz R, Zulauf M, et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNFa and TNFb and inhibition of TNF activity. J Biol Chem 1991; 226:18324-9. (Pubitemid 21908083)
39. Van Zee KJ, Moldawer LL, Oldenburg HAS, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDA TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 1996;156: 2221-30. (Pubitemid 26088573)
40. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:FC fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-702. (Pubitemid 26193621)
41. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277: 1531-8. (Pubitemid 27213302)
42. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-10. (Pubitemid 32225290)
43. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40. (Pubitemid 120028524)
44. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-43. (Pubitemid 24169697)
45. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival in hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
46. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.
47. Taylor FB Jr, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25. (Pubitemid 17050920)
48. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. (Pubitemid 32204987)
49. Abraham E, Laterre PF, Garg R, et al. Administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) study group. N Engl J Med 2005;353:1332-41.
50. Sandrock CE, Albertson TE. Controversies in the treatment of sepsis. Semin Respir Crit Care Med 2010;31:66-78.
51. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
52. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997;277:482-7. (Pubitemid 27074333)
53. Poeze M, Froon AH, Ramsay G, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 2000;14:421-8.
54. Suputtamongkol Y, Intaranongpai S, Smith MD, et al. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 2000;44:693-6. (Pubitemid 30117963)
55. Abraham E, Naum C, Bandi V, et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003;31:718-28. (Pubitemid 36379574)
56. Zeiher BG, Steingrub J, Laterre PF, et al. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005;33:1741-8. (Pubitemid 41153699)
57. López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30. (Pubitemid 38125559)
58. Stephens DP, Thomas JH, Higgins A, et al. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008;36:448-54. (Pubitemid 351158618)
59. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78. (Pubitemid 33010239)
60. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010;38:1685-94.
61. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
62. Adib-Conquy M, Cavaillon J-M. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101: 36-47.
63. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 2008;29:617-25.
64. Baue AE. Multiple, progressive, or sequential systems failure. A syndrome of the 1970s. Arch Surg 1975;110:779-81.
65. Tracey KJ. The inflammatory reflex. Nature 2002;420: 853-9. (Pubitemid 36019638)
66. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007;117:289-96. (Pubitemid 46203953)
67. Rosa-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009;265:663-79.
68. Oke SL, Tracey KJ. The inflammatory reflex and the role of complementary and alternative medical therapies. Ann N Y Acad Sci 2009;1172:172-80.
69. Tracey KJ. Understanding immunity requires more than immunology. Nat Immunol 2010;11:561-4.